- Theratechnologies Inc. (TH) has had its first patient receive a dose of TH1902, for the treatment of sortilin positive (SORT1+) solid tumours
- TH1902 combines Theratechnologies’ proprietary peptide to docetaxel
- TH1902 is Teratechnologies lead PDC stemming from Theratechnologies’ SORT1+ Technology™ in oncology
- It is estimated that the sortilin receptor is expressed in 40 to 90 per cent of cases depending on cancer type
- Theratechnologies Inc. (TH) is down 3.11 per cent and is trading at C$4.36 at 11:42 am ET
Theratechnologies Inc. (TH) has had its first patient receive a dose of TH1902, for the treatment of sortilin positive (SORT1+) solid tumours.
“This is yet another major achievement for our oncology program. Given the important medical need for novel, targeted cancer treatments, the rapid progression of our promising, unique and innovative approach to fighting cancer is a great source of hope for patients,” said Paul Lévesque, President and CEO, Theratechnologies.
“Targeting the sortilin receptor is an exciting and promising new approach for the potential treatment of cancer. Dosing the first patient with TH1902 brings us closer to a potentially much-needed new option in oncology,” said Dr. Satish Shah, Medical Director, Gettysburg Cancer Center, Gettysburg, Pennsylvania and Dr. Tina Khair, Research Director, Gettysburg Cancer Center.
TH1902 combines Theratechnologies’ proprietary peptide to docetaxel.
The U.S. Food and Drug Administration (FDA) recently granted fast track designation to TH1902 as a single agent to treat all advanced solid tumours expressing sortilin that are refractory to standard therapy.
TH1902 is Teratechnologies lead PDC stemming from Theratechnologies’ SORT1+ Technology™ in oncology.
The Canadian Cancer Society and the Government of Québec, through the Consortium Québécois sur la découverte du médicament (CQDM), will contribute a total of 1.4 million dollars towards some of the research currently being conducted for the development of Theratechnologies’ targeted oncology platform at the molecular oncology laboratory of Dr. Borhane Annabi at the Université du Québec in Montréal (UQAM).
The Phase 1 clinical trial includes a dose-escalating part to evaluate the safety, pharmacokinetics, maximum tolerated dose (MTD) and preliminary anti-tumour activity of TH1902 administered once every three weeks patients with advanced solid tumors refractory to available anti-cancer therapies.
Once the MTD is determined, it is planned that a total of 40 additional patients will be enrolled to evaluate the potential anti-tumour activity of TH1902 in patients with endometrial, ovarian, colorectal, pancreatic and triple-negative breast cancers.
Funda Meric-Bernstam, M.D., Chair of the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center is the Lead Principal Investigator of the Phase 1 trial TH1902.
Theratechnologies has developed a peptide that specifically targets sortilin (SORT1) receptors.
SORT1 is expressed in ovarian, triple-negative breast, skin, lung, colorectal and pancreatic cancers. SORT1 plays a significant role in protein internalization, sorting and trafficking, making it an attractive target for drug development.
It is estimated that the sortilin receptor is expressed in 40 to 90 per cent of cases depending on cancer type.
Commercially available anticancer drugs, like docetaxel, doxorubicin or tyrosine kinase inhibitors are conjugated to Theratechnologies’ investigational novel peptides to specifically target sortilin receptors. This could potentially improve the efficacy and safety of those agents.
Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs.
Theratechnologies (TH) is down 3.11 per cent and is trading at C$4.36 at 11:42 am ET.